NCT03820414View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 3, 2019

Primary Completion Date

April 4, 2020

Study Completion Date

April 30, 2020

Conditions
Herpes ZosterVaricella Zoster
Interventions
BIOLOGICAL

CRV 101

(Different formulations)

BIOLOGICAL

Placebo

2 doses administered IM in deltoid region of non-dominant arm

Trial Locations (1)

64114

The Center for Pharmaceutical Research, Kansas City

Sponsors
All Listed Sponsors
collaborator

Access to Advanced Health Institute (AAHI)

OTHER

collaborator

Mogam Biotechnology Research Institute

UNKNOWN

collaborator

Green Cross Corporation

INDUSTRY

lead

Curevo Inc

INDUSTRY

NCT03820414 - Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter